CABOLONG is an advanced oncology-grade formulation of Cabozantinib, designed to target and treat multiple types of cancers with high precision and efficacy. Available in 20mg and 60mg strengths, CABOLONG delivers a powerful therapeutic option for patients diagnosed with various malignancies, including renal cell carcinoma (RCC), hepatocellular carcinoma (HCC), and medullary thyroid cancer (MTC).
The active pharmaceutical ingredient in CABOLONG 60mg is Cabozantinib, a multi-tyrosine kinase inhibitor (TKI) that blocks the activity of several enzymes responsible for tumor growth, angiogenesis (blood vessel formation), and metastatic progression.
What is Cabozantinib?
Cabozantinib is an oral small-molecule inhibitor of multiple receptor tyrosine kinases, including MET, VEGFR, AXL, RET, and others. These kinases play crucial roles in tumor cell proliferation, migration, and survival. By inhibiting these pathways, Cabozantinib halts cancer progression and enhances overall survival rates in patients with advanced or metastatic cancer.
Overview of CABOLONG
CABOLONG 20mg offers a refined formulation of Cabozantinib that adheres to the highest standards of pharmaceutical quality. It is produced under stringent GMP-certified conditions and is intended for use under oncological supervision.
Available Strengths:
CABOLONG 20 mg tablet
CABOLONG 60 mg tablet
Both dosages ensure flexibility in dose titration and personalized treatment based on patient-specific factors such as body weight, organ function, and disease severity.
Indications for CABOLONG Therapy
1. Renal Cell Carcinoma (RCC)
Cabozantinib is indicated for the treatment of patients with advanced renal cell carcinoma, either as a first-line therapy in combination with other agents or as monotherapy following previous treatment with VEGF-targeted therapy.
2. Hepatocellular Carcinoma (HCC)
CABOLONG is highly effective in patients with hepatocellular carcinoma who have been previously treated with sorafenib. It targets the tumor microenvironment and significantly delays disease progression.
3. Medullary Thyroid Cancer (MTC)
For progressive, metastatic medullary thyroid cancer, CABOLONG 20mg offers a targeted approach by inhibiting RET and other kinases involved in the disease's pathophysiology.
Mechanism of Action
Cabozantinib works by blocking multiple tyrosine kinases involved in tumor angiogenesis, growth, and metastasis. These include:
VEGFR-1, VEGFR-2, and VEGFR-3: Inhibition reduces the blood supply to tumors.
MET and AXL: Suppression halts tumor cell migration, invasion, and resistance to therapy.
RET: Critical in medullary thyroid cancer; inhibition controls tumor progression.
By simultaneously targeting several signaling pathways, CABOLONG disrupts the cancer cell lifecycle and enhances the response to treatment.
Pharmacokinetics
Absorption: CABOLONG is well absorbed orally. Peak plasma concentrations occur within 2 to 5 hours post-dose.
Bioavailability: High oral bioavailability ensures effective plasma levels.
Half-life: Approximately 55 hours, supporting once-daily dosing.
Metabolism: Metabolized primarily in the liver via CYP3A4.
Excretion: Eliminated through feces and urine.
Dosage and Administration
Standard Dosage
RCC and HCC: 60 mg orally once daily without food
MTC: 140 mg once daily (may require adjustment based on tolerability)
Administration Guidelines
Take CABOLONG 20mg on an empty stomach, at least 1 hour before or 2 hours after a meal.
Swallow the tablet whole. Do not crush, chew, or split.
Adjust dosage in case of adverse reactions, liver impairment, or drug interactions.
Dose Modifications
Dose adjustments are essential for managing side effects and comorbid conditions. Healthcare providers may reduce the dosage to 40 mg or 20 mg based on the patient's tolerance and response.
CABOLONG's availability in 20 mg and 60 mg strengths allows for accurate and individualized dose titration, minimizing toxicity while maintaining efficacy.
Side Effects and Management
Common Adverse Reactions
Fatigue
Diarrhea
Nausea and vomiting
Decreased appetite
Hand-foot skin reaction
Hypertension
Weight loss
Serious Adverse Events
Gastrointestinal perforations
Hemorrhage
Thromboembolic events
Osteonecrosis of the jaw
Proteinuria
Monitoring Parameters
Blood pressure
Liver function tests
Renal function
Complete blood counts
Electrolyte levels
Healthcare professionals should monitor patients regularly and provide supportive therapy to manage adverse effects. Early detection and prompt dose adjustment are crucial.
Drug Interactions
Cabozantinib is metabolized by the CYP3A4 enzyme, so concomitant use with other drugs that affect CYP3A4 activity should be carefully managed.
Avoid:
Strong CYP3A4 inducers (e.g., rifampin, phenytoin)
Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin)
Use with Caution:
Anticoagulants
Antihypertensives
QT-prolonging agents
Always consult an oncologist or clinical pharmacist before introducing new medications.
Use in Special Populations
Pregnancy and Lactation
Cabozantinib can cause fetal harm. It is contraindicated in pregnancy and should not be used by nursing mothers.
Pediatric Use
Safety and efficacy in pediatric patients remain under investigation. CABOLONG is currently approved only for adult use.
Geriatric Use
Elderly patients may be more susceptible to adverse effects. Start with caution and monitor frequently.
Hepatic Impairment
Dose reduction is recommended in patients with mild to moderate liver impairment. Avoid use in severe hepatic impairment.
Storage and Handling
Store at 25°C (77°F) in a dry place.
Protect from moisture and heat.
Keep out of reach of children.
Dispose of unused tablets according to medical waste protocols.
Advantages of CABOLONG Therapy
High Bioavailability: Efficient systemic absorption ensures therapeutic efficacy.
Flexible Dosing: Two strengths allow for personalized treatment plans.
Oncology-Grade Purity: Manufactured under strict GMP standards.
Multitarget Inhibition: Simultaneously attacks several cancer pathways.
Extended Half-Life: Supports once-daily dosing for convenience and compliance.
CABOLONG vs. Other Cabozantinib Brands
CABOLONG 60mg stands out due to its:
Pharmaceutical-grade purity
Strict quality control
Enhanced tolerability
Cost-effective pricing in comparison to originator brands
Comprehensive clinical support and post-marketing surveillance
Healthcare providers often choose CABOLONG 60mg when seeking an oncology-grade alternative that does not compromise on efficacy or safety.
Clinical Evidence
Multiple Phase III trials, such as METEOR and CELESTIAL, have demonstrated Cabozantinib’s efficacy:
In RCC, cabozantinib significantly improved progression-free survival (PFS) and overall survival (OS).
In HCC, patients showed a 42% reduction in risk of disease progression compared to placebo.
In MTC, cabozantinib led to substantial improvements in tumor response rates and symptom relief.
These results support CABOLONG as a first-choice option for eligible cancer patients.
Patient Support and Education
Educating patients is critical for adherence and successful outcomes. CABOLONG manufacturers often offer:
Patient information leaflets
Hotline support
Adherence programs
Nutritional guidance
Patients should report side effects promptly and follow dietary and dosing instructions meticulously.
Conclusion
CABOLONG 20mg and 60mg represent a powerful advancement in oral oncology therapeutics. With Cabozantinib as its active ingredient, CABOLONG offers a scientifically proven, clinically effective, and patient-friendly option for managing some of the most challenging cancers.
By targeting multiple growth and angiogenesis pathways, CABOLONG 60mg slows cancer progression, improves survival, and enhances quality of life in patients with RCC, HCC, and MTC. Its convenient dosing, excellent tolerability profile, and availability in flexible strengths make it a valuable addition to any oncologist’s arsenal.